MedTrace Logo

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

NCT05387759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-27

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of aticaprant on QT/ QT interval corrected for heart rate (HR) (QTc) intervals and electrocardiogram (ECG) morphology at therapeutic and supratherapeutic exposures in healthy adult participants.

Conditions

  • Healthy

Interventions

DRUG

Aticaprant Supratherapeutic Dose

Aticaprant supratherapeutic dose capsule will be administered orally.

DRUG

Aticaprant Therapeutic Dose

Aticaprant therapeutic dose capsule will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

DRUG

Moxifloxacin

Moxifloxacin capsule will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-30
Primary Completion
2022-10-04
Completion
2022-10-04
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05387759 on ClinicalTrials.gov